The key appears to be the positive impact these products can make on an individual’s gut microbiota.

Orchestra BioMed, Inc., on Sept. 4 announced it received CE mark approval for its Moderato implantable pulse generation system, which delivers the company’s trademarked cardiac neuromodulation therapy to patients while simultaneously acting as a pacemaker.

A study of more than 1,000 Hispanic adults with hypertension found increased health literacy improves patients’ adherence to blood pressure medications—but the majority of the population struggles with poor health literacy, indicating a need for tailored interventions.

Medtronic announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral renal denervation system in patients with high blood pressure (hypertension) who are already prescribed anti-hypertension medications.

Two late-breaking clinical trials presented May 23 at EuroPCR in London demonstrated the ability of renal denervation to significantly lower patients’ blood pressures, regardless of whether they were taking antihypertensive medications.

DUBLIN — April 9, 2018 — Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension).

Research has linked greater segregation within black communities can lead to higher prevalence of hypertension. A recent study, published online May 15 in JAMA Internal Medicine, examined how changes in exposure to segregation affected high blood pressure.